The significance of pre-therapeutic F-18-FDG PET–CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable by Jujuan Wang et al.
1 3
J Cancer Res Clin Oncol (2016) 142:859–871
DOI 10.1007/s00432-015-2094-z
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
The significance of pre‑therapeutic F‑18‑FDG PET–CT 
in lymphoma‑associated hemophagocytic lymphohistiocytosis 
when pathological evidence is unavailable
Jujuan Wang1 · Dongjiao Wang1 · Qingbo Zhang2 · Limin Duan3 · Tian Tian3 · 
Xiaoyan Zhang1 · Jianyong Li1 · Hongxia Qiu1,3 
Received: 29 September 2015 / Accepted: 30 November 2015 / Published online: 15 December 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
significantly higher than those in non-LAHLH group (92.9 
vs. 35.7 %, p = 0.004; 42.9 vs. 0 %, p = 0.016, respec-
tively). Furthermore, by comparing the efficacy of initial 
therapies for highly suspected LAHLH patients (n = 18), 
we indicated that the CR rate was significantly higher in 
lymphoma-chemotherapy group than in immunosuppres-
sive therapy group (90 and 25 %, respectively; p = 0.013). 
OS analysis revealed that highly suspected LAHLH 
patients treated with lymphoma-chemotherapy had better 
prognosis (264 days) than those treated with immunosup-
pressive therapy (15 days) (p < 0.0001).
Conclusions When pathological evidence is absent, PET–
CT may play an important role in identifying HLH patients 
underlying lymphoma. Once highly suspected as LAHLH 
by PET–CT, lymphoma-chemotherapies that directly treat 
the underling lymphoma may have a relatively favorable 
effect and better clinical outcomes than immunosuppres-
sive therapy.
Keywords Lymphoma-associated hemophagocytic 
lymphohistiocytosis (LAHLH) · PET–CT · Differential 
diagnosis · Chemotherapy · Prognosis
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a life-
threatening syndrome of hyper-inflammation, caused by 
uncontrolled activation and proliferation of lymphocytes 
and antigen-presenting cells (macrophages, histiocytes) 
(Filipovich 2009). The disrupted critical regulatory path-
ways, which are responsible for the natural termination 
of immune responses, result in burst release of cytokines. 
The flooding of cytokines, such as IL-6, IL-12, TNF-α, and 
IFN-γ (Emmenegger et al. 2005; Szyper-Kravitz 2009), 
Abstract 
Purpose The significance of positron emission tomog-
raphy/computed tomography (PET–CT) in identifying 
patients with lymphoma-associated hemophagocytic lym-
phohistiocytosis (LAHLH) when pathological evidence is 
unavailable remains uncertain.
Methods In this retrospective study, 44 HLH patients 
who underwent PET–CT before clinical treatment were 
enrolled, and 18 of them were highly suspected as LAHLH 
by PET–CT. We compared the PET–CT parameters 
between confirmed LAHLH and non-LAHLH patients. The 
efficacy of initial therapies for highly suspected LAHLH 
patients was analyzed as well.
Results We found that the SUVSp, SUVBM, SUVLN, 
SUVmax, SUVLN/Li, and SUVmax/Li in LAHLH group were 
significantly higher than those in non-LAHLH group 
(p = 0.003, p = 0.034, p = 0.003, p < 0.001, p = 0.039, 
and p = 0.035, respectively). HLH patients with an SUV-
max value >5.5, an SUVLN value >3.3, and an SUVSp value 
>4.8 were more likely to be LAHLH (p < 0.001, p = 0.003, 
and p = 0.003, respectively). And the incidence of multi-
ple lymphadenopathy with increased FDG uptake or the 
incidence of multiple bone lesions in LAHLH patients was 
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leads to the typical clinical manifestations, such as hepato-
splenomegaly, persistent high fever, cytopenia, dysfunction 
of liver and hepatitis. In addition, the rapid progression 
and extremely high mortality rate of HLH despite proper 
management (Kaito et al. 1997) frustrate both patients and 
physicians.
Based on the presence or absence of hereditary disor-
der, HLH can be classified into primary HLH and second-
ary HLH. Primary HLH, known as familial HLH (FHL), is 
a disease caused by mutations in the genes with a median 
survival of less than 2 months after diagnosis if not treated 
(Henter et al. 2007). The first onset of FHL is at infancy 
or at early childhood (Henter et al. 2007). Secondary HLH 
(sHLH) may develop as a result of strong immune activa-
tion in association with severe infections, malignancies, or 
autoimmune diseases. Accordingly, it is, respectively, clas-
sified as infection-associated HLH (IAHLH), malignancy-
associated HLH (MAHLH) (Janka et al. 1998), and rheu-
matic autoimmune diseases-associated HLH (RAHLH). 
In addition, there are some idiopathic HLH patients, from 
whom confirmed etiological factors are unavailable (Kim 
et al. 2013). Further studies about identifying the causative 
agents and finding efficacious regimens to these specific 
sHLH patients are seldom reported.
F-18 fluoro-2-deoxyglucose positron emission tomog-
raphy/computed tomography (F-18 FDG PET–CT) is a 
functional imaging technique. It can not only correctly 
describe the morphologic and metabolic states of the 
lesions, but also check the infiltrated lymph nodes, spleen, 
bone marrow, and other extranodal organs, which are usu-
ally neglected by conventional imaging examinations (de 
Jong et al. 2009). Therefore, it plays an important role in 
the diagnosis, staging, post-therapeutic follow-up, and 
prognosis of many malignancies. In the case of lymphoma, 
PET identified >97 % of disease sites of Hodgkin lym-
phoma (HL) and aggressive and highly aggressive non-
Hodgkin lymphoma (Henter et al. 2007). It also localizes 
suitable sites of biopsy that is accurate for baseline stag-
ing in the absence of palpable lymphadenopathy, and yields 
important prognostic information for determining the most 
appropriate initial treatment (Cronin et al. 2010).
So far, little research has described the characteristic 
findings of F-18 FDG PET–CT in patients with HLH. Our 
previous study reported that the maximum standardized 
uptake value (SUVmax) of patients in MAHLH group was 
significantly higher than of patients in IAHLH group or 
RAHLH group (Zhang et al. 2012). Therefore, we hypothe-
sized that, for sHLH patients with out known etiology, F18-
FDG PET–CT might provide beneficial data in distinguish-
ing lymphoma-associated HLH (LAHLH) patients and in 
determining a better initial therapy.
To research these issues, the aims of the present study 
were to:
1. Investigate the characteristics of F-18 FDG PET–CT 
image in patients with sHLH. Find out the differences 
of F-18 FDG PET–CT characteristics between LAHLH 
and non-lymphoma-associated HLH (non-LAHLH).
2. Discuss the diagnostic performance of PET–CT for the 
detection of underlying lymphoma, especially when 
pathological evidences were unavailable.
3. Compare the efficacy of different regimens for LAHLH 
without pathological basis. Explore the significance of 




There were total of 44 adult patients newly diagnosed 
with HLH who had undergone F-18 FDG PET–CT scan-
ning before clinical treatment between February 2011 and 
December 2014. They were enrolled in this retrospec-
tive analysis. HLH was diagnosed according to the diag-
nostic criteria of HLH-2004 protocol (Group 2004). In 
order to ascertain the diagnosis of HLH and find out pos-
sible underlying diseases, a series of laboratory tests and 
equipment inspections were selectively and systematically 
performed, including blood, bone marrow, or sputum cul-
ture: PCR tests of virus DNA loads (such as Epstein–Barr 
virus, cytomegalovirus, hepatitis virus); screening of tumor 
markers and autoimmune indicators; CT scans; bone mar-
row aspiration and biopsy; and lymph node biopsy in 
some cases. Fourteen of these patients were identified as 
lymphoma-associated HLH (LAHLH) (among them, nine 
had a pathological basis of lymphoma at first visit and five 
lacked evidence of lymphoma in the early stage of the dis-
ease and confirmed diagnosis after chemotherapy started), 
11 patients as IAHLH, three patients as RAHLH. The three 
RAHLH patients met authoritative diagnostic criteria after 
combining clinical symptoms and signs with laboratory 
tests and imaging findings. No etiology factors were found 
in the other 16 patients. The distribution of etiologies of the 
44 patients with HLH is presented in Table 1.
For each patient, we collected the following information: 
age, sex, presence of fever and splenomegaly, routine blood 
count tests, blood biochemical tests (including triglyceride, 
aspartate aminotransferase, alanine aminotransferase, and 
lactate dehydrogenase), fibrinogen, serum ferritin, serum 
soluble interleukin-2 receptor (sIL-2R, sCD25), C-reactive 
protein (CRP), and lymphocyte subsets tests including 
proportion of CD3+, CD3+/CD4+, CD3+/CD8+, CD3-
CD16+CD56+. Bone marrow aspiration and biopsy were 
done at the time of initial diagnosis. Type of initial therapy 
and outcome of treatment were also reviewed.
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Image acquisition
The F-18 FDG PET–CT images were acquired from 
the skull base to the upper thigh with a special-purpose 
PET–CT scanner (Discovery ST, GE Healthcare). Before 
the examination was done, patients were asked to be 
fasting for at least 6 h to control blood glucose level 
lower than 7.0 mmol/L. All patients received an F-18 
FDG dose of 3.7–5.55 MBq/kg by intravenous injec-
tion. In a quiet state, the distribution of this tracer in the 
human body needed a period of time, and the mean time 
from F-18 FDG injection to imaging was 60 min. CT 
data were used for attenuation correction, and images 
were reconstructed by using a conventional iterative 
algorithm. Tomographic slice thickness was designed 
as 5 mm. Ultimately, fusion images of PET and CT on 
cross-sectional plane, sagittal plane, and coronal plane 
were obtained. The standardized uptake value (SUV) is 
the measured activity at the region of interest, which is 
normalized for body weight/surface area and injected 
dose.
Image analysis
PET–CT images were reviewed by experienced nuclear 
medicine physicians on a dedicated workplace. To measure 
the maximum SUV in the spleen and liver, round (or ellipti-
cal) regions of interest (ROIs) were drawn on the center of 
the spleen or right lobe of the liver, respectively. Also round 
ROIs were drawn over the thoracic (T10–12) and lum-
bar (L2–4) vertebral bodies and enlarged lymph nodes to 
measure bone marrow and lymph nodes activity. Then, the 
maximum SUV of the bone marrow, spleen, lymph nodes, 
and liver was described in our study as SUVBM, SUVSp, 
SUVLN, and SUVLi, respectively. Excluded the sites of 
which increased SUV value were considered as physiologi-
cal uptake, the highest whole body SUV value was set as 
SUVmax. SUVBM/Li was calculated by dividing SUVBM by 
SUVLi. SUVSp/Li and SUVmax/Li were calculated as the same.
Other information of PET–CT findings which could 
not be described by SUV levels was collected. The pres-
ence of splenomegaly, hepatomegaly, pulmonary inflam-
matory lesions, liver lesions, and effusions; sites and num-
bers of lymphadenopathy and bone lesions were enrolled. 
The presence of lymphadenopathy in three or more lymph 
node regions was defined as multiple lymphadenopathy. 
Bone lesions were referred to bone sites where SUV level 
increased. Degenerative changes such as hyperosteogeny 
were excluded. Similarly, the presence of increased FDG 
uptake in three or more bone regions was defined as mul-
tiple bone lesions. Pulmonary inflammatory lesions were 
referred to pneumonia, atelectasis or bronchiectasis. And 
liver cyst and fatty liver were included in liver lesions.
Treatment group
A total of 13 HLH patients who had no clear etiology fac-
tor were highly suspected as lymphoma by PET–CT detec-
tion. And another five confirmed lymphoma-associated 
patients who lacked pathological evidence in the early 
stage of the disease were highly suspected as lymphoma by 
PET–CT, as well. In all, 18 patients were highly suspected 
as LAHLH by initial PET–CT. For further research of the 
initial therapeutic regimen of patients who were highly 
suspected as LAHLH by PET–CT without clear pathologi-
cal evidences, they were grouped according to their initial 
therapy. Suspected LAHLH patients treated with chemo-
therapy (n = 13), which usually applied to lymphoma, 
were enrolled in lymphoma-chemotherapy group. Other 
suspected LAHLH patients treated with immunosuppres-
sive therapy (n = 5) which was mainly focused on sup-
pressing excessive immune response and cytokine storm 
were enrolled in immunosuppressive therapy group.
Table 1   Distribution of etiologies in 44 patients with HLH
a Three cases of T cell lymphoma, b one case of peripheral T cell 
lymphoma, and c one case of B cell lymphoma who lacked pathologi-
cal evidence initially were highly suspected as lymphoma by PET–
CT (n = 5). They were confirmed as lymphoma according to their 
pathological evidence which were got after treatment or in the end 
stage of the disease
Etiologies Number
Unexplained HLH 16 (36.4 %)
 Highly suspected lymphoma by PET–CT 13
 Others 3
Lymphoma-associated HLH 14 (31.8 %)
 DLBCL 4
 T cell lymphoma 4a
 Peripheral T cell lymphoma 2b
 B cell lymphoma 2c
 Hodgkin’s lymphoma 1
 NK/T cell lymphoma 1
Infection-associated HLH 11 (25.0 %)
 EBV 5
 CMV 1
 Herpes virus 1
 Pulmonary infection 3
 Staphylococcus sepsis 1
Autoimmune disorder-associated HLH 3 (6.8 %)
 Adult Still’s disease 1
 Systemic lupus erythematosus 1
 Sjogren’s syndrome 1




In lymphoma-chemotherapy group, eight patients received 
EPOCH chemotherapy (Gutierrez et al. 2000) or dose-
adjusted EPOCH (DA-EPOCH) chemotherapy (Wilson 
et al. 2008), four patients adopted CHOP chemotherapy 
(Pfreundschuh et al. 2008), and one patient was given 
hyper-CVAD-A chemotherapy (Thomas et al. 2004). 
Extensional schemes are not described in detail here.
Protocols that were aimed directly at super cytokine 
storm and hyper-inflammation were used in five patients 
of immunosuppressive therapy group. They were given 
high-dose corticosteroid combined with intravenous immu-
noglobulin (IVIG) pulse therapy, which was consisted of 
Dex 10 mg/(m2 day) i.v. daily and immunoglobulin 0.4 g/
(kg day) for 5 days.
Supportive therapy
According to bacterial or fungal culture results, appropriate 
or even experienced broad-spectrum antibiotics and anti-
mycotics were used. Antiviral drugs were included in the 
supportive therapy in infected patients. IVIG and intrave-
nous human albumin were used when required. Liver pro-
tection and treatment to jaundice were performed. Blood 
component transfusion, including erythrocyte suspension, 
platelets, fresh-frozen plasma, and cryoprecipitate, was 
adopted. In some cases, granulocyte colony-stimulating 
factor (G-CSF), erythropoietin (EPO), and thrombopoietin 
(TPO) were given as needed. Certainly, proper supportive 
care was also essential.
Treatment response evaluation
Clinical response (CR) was defined as explicit fulfillment 
of all criteria including: (1) no fever; (2) reduction in spleen 
size; (3) platelets >100 × 109/L; (4) normal fibrinogen; 
(5) decreasing ferritin levels (by 25 %) (Group 2004). No 
response (NR) was considered if not all criteria were ful-
filled. The evaluation of disease status was done 1–2 weeks 
after finishing the initial therapy.
Statistical analysis
Statistical analyses were performed with commercial soft-
ware package (SPSS, version 17.0, Chicago, IL, USA). Sta-
tistical significance was determined at a level of p < 0.05. 
PET–CT parameters of LAHLH group and non-LAHLH 
group were compared using Mann–Whitney U test. Occur-
rence rate of other PET–CT findings in LAHLH and non-
LAHLH group was compared using Fisher’s exact test. 
To identify an optimal cutoff for each PET–CT parameter, 
receiver operating characteristic (ROC) analysis was per-
formed. Correlations between PET parameters and labora-
tory parameters were assessed using the Spearman corre-
lation test. The overall survival (OS) was calculated from 
the time of diagnosis to the time of death or last follow-up 
and was analyzed combined with survival curves using the 
Kaplan–Meier method. Differences between curves were 
tested using the log-rank test.
Results
PET–CT characteristics of sHLH and differences 
of PET–CT characteristics between LAHLH 
and non‑LAHLH
We summarized the PET–CT characteristics of the 44 
patients with sHLH who were admitted into our hospi-
tal and underwent the PET–CT examination. The male to 
female ratio was 1.25, and medium age was 42 years (29–
60). All of the patients had at least three organs involved, 
including 37 cases (82.2 %) showing splenomegaly (among 
them 28 cases with increased SUVSp), 35 cases (77.8 %) 
with bone lesions, 34 cases (75.6 %) lymphadenopathy (31 
cases with increased SUVLN), 35 cases (77.8 %) inflam-
matory changes in the lung including pneumonia and/or 
atelectasis, 29 cases (64.4 %) serous effusions (in pleural 
cavity, peritoneal cavity, pelvic cavity, and/or pericardial 
cavity), 26 cases (57.8 %) pleura thickening and/or pleura 
adhesion, 17 cases (37.8 %) cholecystitis or cholelithiasis, 
16 cases (35.6 %) sinusitis, 15 cases (33.3 %) heart lesions 
(mainly lower density of the heart chamber than the heart 
wall), 13 cases (28.9 %) brain tissue or cerebrovascular 
lesions, 10 cases (22.2 %) hepatomegaly (all accompanied 
by increased SUVLi, another three cases revealed no hepa-
tomegaly but increased SUVLi), and eight cases (17.8 %) 
pericardium thickening. Other involved organs were kid-
ney, mammary gland, muscles, oropharynx, and adnexa 
uteri.
To better distinguish LAHLH patients from HLH 
patients, patients were divided into three groups: LAHLH 
group (n = 14), non-LAHLH group (n = 14) (includ-
ing IAHLH and RAHLH), and unexplained causes group 
(n = 16). We compared the PET–CT parameters between 
LAHLH and non-LAHLH patients, including SUVSp, 
SUVLi, SUVBM, SUVLN, SUVmax, SUVSp/Li, SUVBM/Li, 
SUVLN/Li, and SUVmax/Li. Nonparametric test showed that 
the levels of SUVSp, SUVBM, SUVLN, SUVmax, SUVLN/Li, 
and SUVmax/Li in LAHLH group were significantly higher 
than those in non-LAHLH group (p = 0.003, p = 0.034, 
p = 0.003, p < 0.001, p = 0.039, and p = 0.035, respec-
tively). However, the levels of SUVLi, SUVSp/Li, and 
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SUVBM/Li in two groups revealed no significant difference. 
The medians and interquartile ranges of different PET–CT 
parameters are given in Table 2.
ROC curves demonstrated that a SUVmax of 5.5, a 
SUVLN of 3.3, and a SUVSp of 4.8 were the optimal cut-
offs to distinguish LAHLH patients from non-LAHLH 
patients. HLH patients with an absolute SUVmax value >5.5 
were more likely to be LAHLH than those with a lower 
SUVmax value (p < 0.001, sensitivity = 92.9 % and speci-
ficity = 85.7 %, AUC = 0.923). Similarly, HLH patients 
with an absolute SUVLN value >3.3 or an absolute SUVsp 
value >4.8 were more likely to be LAHLH (p = 0.003, sen-
sitivity = 78.6 % and specificity = 78.6 %, AUC = 0.834; 
p = 0.003, sensitivity = 71.4 % and specificity = 100 %, 
AUC = 0.832) (see Table 3).
Table 4 shows the positive rate of other PET–CT find-
ings in LAHLH and non-LAHLH group. Thirteen out of 
14 (92.9 %) patients in LAHLH group and five out of 14 
(35.7 %) patients in non-LAHLH group had multiple lym-
phadenopathy accompanied by increased FDG uptake. 
The incidence of multiple lymphadenopathy accompanied 
by increased FDG uptake in LAHLH patients was signifi-
cantly higher than those in non-LAHLH group (p = 0.004). 
Six out of 14 (42.9 %) LAHLH patients had multiple bone 
lesions, and none of the non-LAHLH patients (0 %) had 
multiple bone lesions. The incidence of multiple bone 
lesions in LAHLH patients was significantly higher than 
those in non-LAHLH group (p = 0.016). No significant dif-
ference was found in the incidence of splenomegaly, hepa-
tomegaly, pulmonary inflammatory lesions, liver lesions, 
and effusions between the two groups.
Clinical characteristics, treatment outcome, 
and survival analysis
The cardinal features of the 18 highly suspected LAHLH 
patients were persistent high fever, pancytopenia, raised 
transaminases, hyperbilirubinemia, respiratory failure, 
Table 2  PET–CT parameters in LAHLH and non-LAHLH group
* Difference of PET–CT parameter between two groups is significant 
at p < 0.05
** Difference of PET–CT parameter between two groups is signifi-




LAHLH (n = 14) Non-LAHLH 
(n = 14)
SUVSp 5.7 (2.7–10.8) 2.0 (1.8–3.6) 0.003**
SUVBM 6.9 (2.2–10.0) 2.5 (2.0–3.7) 0.034*
SUVLi 2.1 (1.9–8.1) 2.0 (1.7–2.2) 0.079
SUVLN 10.6 (3.3–13.6) 2.3 (1.9–3.5) 0.003**
SUVmax 12.8 (8.2–16.2) 4.3 (2.7–5.2) 0.000**
SUVSp/Li 1.4 (1.0–2.7) 1.0 (0.8–1.6) 0.057
SUVBM/Li 1.5 (0.9–4.4) 1.2 (0.9–1.8) 0.581
SUVLN/Li 2.3 (1.1–6.5) 1.1 (0.9–1.6) 0.039*
SUVmax/Li 4.3 (1.7–6.5) 2.3 (1.1–2.8) 0.035*
Table 3  ROC analysis of PET–CT parameters in distinguishing 
LAHLH patients (n = 14) from non-LAHLH patients (n = 14)
* Significance at p < 0.05
** Significance at p < 0.01





SUVSp 4.8 0.832 71.4 100 0.003**
SUVBM 4.5 0.735 64.3 92.9 0.035*
SULLi 6.4 0.694 28.6 100 0.081
SUVLN 3.3 0.834 78.6 78.6 0.003**
SUVmax 5.5 0.923 92.9 85.7 0.000**
SUVSp/Li 1.0 0.712 92.9 42.9 0.057
SUVBM/Li 1.7 0.561 50.0 78.6 0.581
SUVLN/Li 1.4 0.730 71.4 78.6 0.039*
SUVmax/Li 2.8 0.735 64.3 78.6 0.035*
Table 4   Positive rate of other 
PET–CT findings in LAHLH 
and non-LAHLH group




LAHLH (n = 14) Non-LAHLH (n = 14)
Splenomegaly 13/14 (92.9 %) 9/14 (64.3 %) 0.165
Hepatomegaly 2/14 (14.3 %) 2/14 (14.3 %) 1
Multiple lymphadenopathy 13/14 (92.9 %) 5/14 (35.7 %) 0.004**
Multiple bone lesions 6/14 (42.9 %) 0/14 (0 %) 0.016**
Pulmonary inflammatory lesions 10/14 (71.4 %) 12/14 (85.7 %) 0.648
Liver lesions (hepatic cyst and fatty liver) 6/14 (42.9 %) 4/14 (28.6 %) 0.695
Effusions 7/14 (50.0 %) 11/14 (78.5 %) 0.236
864 J Cancer Res Clin Oncol (2016) 142:859–871
1 3
and DIC tendency. They also had manifestations of lym-
phoma, such as night sweats, weight loss, enlarged lym-
phohematopoietic organs, and markedly elevated LDH 
and β2-microglobulin. Imaging examinations showed lym-
phoma-like lesions in PET–CT, as well. However, due to 
the absence of enlarged superficial nodes and rapid dete-
rioration of vital signs, biopsies of deep lymph nodes or 
splenic resection were unavailable.
The cutoff time was April 30, 2015. The median sur-
vival time of 18 patients who were highly suspected as 
LAHLH by initial PET–CT was 92 days (interquartile 
range, 27–436 days). Table 5 shows the response rate 
and median survival time of two groups. Ten out of 13 
patients showed clinical response after initial lymphoma-
chemotherapy; however, none showed clinical response 
in the immunosuppressive therapy group. The clinical 
response rate was significantly higher in lymphoma-
chemotherapy group than in immunosuppressive ther-
apy group (76.9 and 0 %, respectively; p = 0.007). The 
median survival time of lymphoma-chemotherapy group 
and immunosuppressive therapy group was 264 and 
15 days, respectively. OS analysis revealed a significant 
difference on survival rate between the two groups by 
log-rank test (p < 0.0001) (Fig. 1). Therefore, for initial 
regimen of highly suspected LAHLH, lymphoma-chemo-
therapy has more curative efficacy than immunosuppres-
sive therapy.
Table 6 shows treatment courses and prognosis of highly 
suspected LAHLH patients receiving different initial treat-
ment. Patients received CR and had a long survival time, 
except patient no. 8 who revealed no response to chemo-
therapy and died 1 month later, and patient no. 4 who got 
CR after initial chemotherapy but died of interruption of 
continuation therapy. Among these, post-therapeutic PET–
CT was done on five patients (patient no. 2, 3, 5, 9, and 10) 
after completion of initial chemotherapy or several cycles 
of chemotherapy. Complete or major resolution of FDG-
avid lesions was observed including spleen, liver, lymph 
nodes, and bone, suggesting markedly improved condition; 
see Figs. 2 and 3.  
Five patients with highly suspected LAHLH were ini-
tially administered high-dose corticosteroid plus IVIG 
(immunosuppressive therapy). All of them showed no 
response and died within 4 weeks. One of them (patient no. 
15) received post-treatment PET–CT after receiving high-
dose corticosteroid plus IVIG. Although his spleen was 
slightly smaller than before which could be observed on 
PET–CT re-examination, diffuse intense FDG uptake was 
not relieved at all. In addition, diffuse patchy heterogene-
ous pattern of FDG uptake on his humeri was displayed, 
suggesting poor efficacy (shown in Fig. 4).
Diagnostic performance of PET–CT for detection 
of lymphoma in HLH patients
Among 18 HLH patients who were highly suspected as 
lymphoma by PET–CT, five patients (patient no. 4, 5, 6, 9, 
and 10) ultimately received pathological confirmation of 
lymphoma. Of these, one had peripheral T cell lymphoma, 
one had B cell lymphoma, and three had T cell lymphoma 
Table 5  Response rate of initial treatment and median survival time of 18 patients who were highly suspected as LAHLH by preliminary 
PET–CT
Lymphoma-chemotherapy group refers to suspected LAHLH patients treated with lymphoma-chemotherapy; immunosuppressive therapy group 
refers to suspected LAHLH treated with high-dose corticosteroid and IVIG
** Significance at p < 0.01
Group Response Median survival time (days), median (interquartile range)
CR NR
Lymphoma-chemotherapy group 10/13 (76.9 %) 3/13 (23.1 %) 264 (92–596)
Immunosuppressive therapy group 0/5 (0 %) 5/5 (100 %) 15 (12–17)
p value p = 0.007**
Fig. 1  Kaplan–Meier survival of 18 highly suspected LAHLH 
patients treated with lymphoma-chemotherapy and immunosuppres-
sive therapy. Kaplan–Meier analysis revealed a significant difference 
on OS between lymphoma-chemotherapy group and immunosuppres-
sive therapy group by log-rank test (p < 0.0001)
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Table 6  Treatment courses and prognosis of 18 highly suspected LAHLH patients receiving different initial treatment
F, female; M, male; PTCL, peripheral T cell lymphoma; Hyper-CVAD-A, cyclophosphamide, mesna, vincristine, doxorubicin, dexamethasone; 
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; EPOCH, etoposide + CHOP; DA-EPOCH, dose-adjusted EPOCH; IVIG, 
intravenous immunoglobulin; GDP, gemcitabine, dexamethasone, cisplatin; MINE, mitoxantrone, ifosfamide, mesna, etoposide; l-GDP, l-aspar-
aginase + GDP; CR, clinical response; NR, no response
No. Age/sex Diagnose Initial treatment Initial treatment 
response
Continuous treatment Survival (days) Prognosis
1 25/M Highly suspected 
lymphoma
DA-EPOCH CR 1 cycle 
EPOCH + splenic 
radiotherapy + 1 
cycle MINE
190 Survival
2 43/F Highly suspected 
lymphoma
DA-EPOCH CR 3 cycles 
EPOCH + 2 cycles 
MINE + splenic 
radiotherapy
652 Survival
3 44/M Highly suspected 
lymphoma
DA-EPOCH CR 3 cycles DA-
EPOCH + 3 cycles 
GDP + 1 cycle 
MINE
206 Died
4 71/F Highly suspected 
lymphoma → T cell 
lymphoma
CHOP CR – 74 Died
5 55/M Highly suspected 
lymphoma → T cell 
lymphoma
CHOP CR 1 cycle 
CHOP + splenic 
resection + 1 cycle 
Hyper-CVAD-A + 2 
cycles MINE
596 Died
6 32/M Highly suspected 
lymphoma → T cell 
lymphoma




7 41/F Highly suspected 
lymphoma
EPOCH CR 4 cycles EPOCH + 1 
cycle L-GDP
437 Died
8 48/F Highly suspected 
lymphoma
DA-EPOCH NR – 33 Died
9 60/M Highly suspected 
lymphoma → B cell 
lymphoma
DA-EPOCH CR 5 cycles DA-
EPOCH + 2 cycles 
DHAP + 1 cycle 
MINE
264 Died
10 25/F Highly suspected lym-
phoma → PTCL




11 36/M Highly suspected 
lymphoma
CHOP NR – 35 Died
12 65/F Highly suspected 
lymphoma
CHOP CR 2 cycles CHOP 115 Died
13 69/M Highly suspected 
lymphoma
Hyper-CVAD-A NR – 92 Died




NR – 12 Died




NR – 27 Died




NR – 8 Died




NR – 17 Died




NR – 15 Died
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(see Table 6). Lymphoma was confirmed by bone marrow 
biopsy in patient no. 4, 6, and 9 after initial chemotherapy; 
by bone marrow biopsy in patient no. 5 in the end stage of 
the disease; and by a second cervical lymph node biopsy 
in patient no. 10. Therefore, these cases confirmed that 
PET–CT plays an important role in detection of lymphoma 
in HLH patients without pathological basis. PET–CT and 
pathological examination are consistent in the diagnosis of 
lymphoma to a certain extent. Pathological evidence was 
unavailable for the other 13 patients. Among them, five out 
of eight patients who accepted lymphoma-chemotherapy 
showed satisfactory clinical response, including normal 
body temperature, reduction in spleen and lymph node size, 
recovery of blood cell counts, normal fibrinogen, decreas-
ing levels of ferritin, LDH, transaminases, and bilirubin. 
None of the five patients on immunosuppressive therapy 
showed clinical response (see Table 6). Their better effica-
cies with lymphoma-chemotherapy than with immunosup-
pressive regimen indirectly showed the reliability of PET–
CT to diagnose them as LAHLH. There is no doubt that 
pathological biopsy is most important in the management 
of adult HLH patients. But for those HLH patients who 
are in critical condition and are unavailable to pathologi-
cal biopsy and other etiological factors, PET–CT might be 
Fig. 2  Comparison of PET–CT images of patient no. 2 who was 
highly suspected as lymphoma-associated HLH by PET–CT before 
lymphoma-chemotherapy and after treatment. a Initial PET–CT scan 
revealed FDG-avid splenomegaly with a SUVSp of 10.5 but no dis-
ease elsewhere (arrow). b Follow-up PET–CT scan was performed 
after receiving two cycles of EPOCH chemotherapy. It revealed sig-
nificantly reduced spleen with no FDG-hypermetabolism (arrow). 
Until the date of cutoff time, the patient has survived for 652 days
Fig. 3  Comparison of PET–CT 
images of patient no. 9 before 
treatment and after lymphoma-
chemotherapy. a Pre-therapeutic 
coronal PET–CT showed 
multiple FDG-avid lymph nodes 
around abdominal aorta (trian-
gle), diffuse FDG uptake within 
enlarged spleen (arrow), and 
patchy FDG-avid lesions in ster-
num, clavicles, humerus, iliac 
bones, and multiple vertebral 
bodies (arrowhead). b After 
administered six cycles of DA-
EPOCH chemotherapy, PET–
CT revealed resolution of the 
metabolically active disease in 
multiple lymph nodes, spleen, 
and multiple bones, suggesting 
favorable efficacy of the previ-
ous chemotherapies. Until the 
date of cutoff time, the patient 
has survived for 264 days
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of help in screening for potentially undetected lymphoma. 
Certainly, conclusions on primary triggers should be drawn 
carefully. Decisions about etiological factors and more 
appropriate therapies should be made by integrating pre-
treatment PET–CT with clinical manifestations and labora-
tory results.
Discussion
First described by Farquhar and Claireaux in 1952, HLH 
has a rapidly fatal clinical course. Familial HLH occurs 
due to known genetic defects (Ahn et al. 2010; Farquhar 
and Claireaux 1952), while secondary HLH may occur in 
association with severe infections, autoimmune diseases, or 
malignancies. However, the etiology distributions of sec-
ondary HLH vary a lot in different researches. A seminar 
paper summarized the causes of 2197 adult HLH, report-
ing about 50 % of infection and 57 % of neoplasms associ-
ated cases (Ramos-Casals et al. 2014). In a study of adult 
HLH patients, the causative factors were EBV (53.3 %), 
idiopathic (23.3 %), lymphoma (13.3 %), and other causes, 
with overall response rate of 50 % and mortality of 50 % 
(Ahn et al. 2010). In a recent study of 69 patients with sec-
ondary HLH from a single center of China, unexplained 
causes were responsible for 36.2 % of the cases, followed 
by infectious (33.3 %), lymphoma (21.7 %), and autoim-
mune disorders (7.2 %) (Li et al. 2014). In a previous study 
of our group, which introduced the application of COP 
regimen in treating sHLH, 46.7 % were infection-associ-
ated HLH, 26.7 % were cases with the absence of apparent 
underling diseases, 13.3 % were LAHLH, and 13.3 % were 
autoimmune disease-associated ones. In a recent retrospec-
tive study on sHLH from causes other than lymphoma, 
EBV infection (69.6 %) and idiopathic causes (26.1 %) 
consisted the main part of the whole (Park et al. 2012). As 
a consequence, we believe that lymphoma and unexplained 
ones account for a large part of sHLH. In our presented ret-
rospective analysis, 14 patients (31.1 %) were classified as 
LAHLH, 5 (11.1 %) as EBV infection-associated HLH and 
16 (35.6 %) as unexplained HLH. Since only newly diag-
nosed HLH patients who had undergone PET–CT before 
treatment were enrolled in our study, there may be statistic 
bias in the distribution of etiology in our paper. Although 
due to various etiologies, patient characteristics, severity of 
complications, or underlying medical conditions, the clini-
cal responses and mortality rates may differ a lot among 
different studies, the overall prognosis of sHLH is quite 
poor.
Diagnostic criteria have been well proposed and updated; 
however, it is still challenging to make a diagnosis of HLH 
since most of the clinical and laboratory features are non-
specific. Distinguishing extremely ill patients with mul-
tiorgan failure from HLH is difficult, since they have many 
common features (Tothova and Berliner 2014). Additionally, 
some patients could be diagnosed with sHLH in accordance 
with the diagnostic criteria, but no primary disease could be 
determined. Some other patients showed enlarged lymph 
nodes in the depth of the body or splenomegaly from imag-
ing examinations. In the absence of enlarged superficial 
nodes, biopsies were unavailable. Biopsies of deep lymph 
nodes (such as para-aortic or retroperitoneal lymph nodes) 
or splenic resection were not recommended. Forced surgery 
could accelerate or even directly lead to death.
Fig. 4  Comparison of PET–CT 
images of patient no. 15 before 
and after immunosuppressive 
therapy. a Initial PET–CT scan 
revealed FDG-avid spleno-
megaly with a SUVSp of 8.6 
(arrow). b After receiving 
immunosuppressive therapy, 
post-therapeutic PET–CT 
revealed slightly smaller size 
in spleen; however, diffuse 
intense FDG uptake was higher 
than before with a SUVSp of 
15.6 (arrow). In addition, new 
patchy FDG-avid lesions in 
humeri were shown, suggesting 
poor efficacy (not shown here). 
This patient survived for only 
27 days
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The imaging manifestations of HLH, which have lots of 
overlap in inflammation and hematological malignancy, are 
unspecific. Many researches have reported increased FDG 
uptake level in the spleen of patients with hematopoietic 
diseases and various infectious, like malignant lymphoma, 
acute virus infection, and infectious mononucleosis (Liu 
2009; Lustberg et al. 2008; Sheehy and Israel 2007; Tomas 
et al. 2000). In a case report of T cell lymphoma-associ-
ated HLH with liver involvement, PET–CT showed diffuse 
intense FDG uptake in the enlarged liver and spleen, with 
systemic FDG-avid lymphadenopathy. In a study of 766 
lymphoma patients, scholars indicated that with the excep-
tion of extranodal marginal zone lymphoma and small 
lymphocytic lymphoma, most lymphoma subtypes have 
high 18 F-FDG avidity (Weiler-Sagie et al. 2010). In our 
present study, the most common feathers of sHLH patients 
were splenomegaly and/or lymphadenopathy with various 
degrees of increased FDG uptake and bone lesions with 
increased FDG uptake. Inflammatory changes in the chest 
were generally observed as well, including pneumonia, 
atelectasis, pleura thickening, pleura adhesion, and hydro-
thorax. High levels of cytokines have been identified in the 
pleural fluid of patients with virus-associated HLH (Ohga 
et al. 1993). Therefore, we though that strong cytokine 
storm in lung tissue or infection due to neutropenia or dys-
function of immune system may result in these changes. 
Other common PET–CT feathers comprised inflammatory 
changes in the gallbladder, sinusitis, brain lesions, hepa-
tomegaly, and lower density of the heart chamber than the 
ventricular wall which reflected an anemic state. Chung 
(2007) presented brain histology findings of HLH in the 
early stage, including lymphocytic leptomeningeal infil-
tration with hemophagocytosis and proliferation of histio-
cytes in the meninges, brain parenchyma, and perivascular 
spaces. They also observed calcification and necrosis of 
putamen, internal capsule, thalamus, and demyelination of 
white matter on MRI during disease progression. Fitzgerald 
and MacClain (2003) reported MRI manifestations of 18 
HLH patients, mainly included abnormal signals of white 
matter, brain atrophy, and cerebral ventricle dilatation. In 
our study, a total of 13 cases had brain lesions, involving 
five cases reduced and one case increased uptake level of 
cerebral cortex, four cases infarction, two cases atrophy, 
and one case cerebral aneurysm. However, none of the six 
cases who had changed FDG uptake level in cerebral cortex 
showed clinical manifestations of central nervous system 
infiltration.
Further investigation in clinical or laboratory charac-
teristics of sHLH may be of benefit to make early differ-
ential diagnosis. Our previous study found that SUVmax 
may especially play impotent role in differential diagno-
sis of sHLH (Zhang et al. 2012). In the present study, we 
conclude that not only SUVmax, but also SUVSp, SUVBM, 
SUVLN, SUVLN/Li, and SUVmax/Li may be of significance 
in the differential diagnosis of LAHLH. We compara-
tively analyzed the PET–CT features of LAHLH and non-
LAHLH and found that patients in LAHLH group had a 
markedly higher level of SUVSp, SUVBM, SUVLN, SUVmax, 
SUVLN/Li, and SUVmax/Li than those in non-LAHLH group 
(p = 0.003, p = 0.034, p = 0.003, p < 0.001, p = 0.039, 
and p = 0.035, respectively). As a result, SUVmax higher 
than 5.5, SUVLN higher than 3.3, and SUVSp higher than 
4.8 could be used as differential diagnosis to distinguish 
LAHLH from sHLH, wherein SUVmax had a high diag-
nostic accuracy (AUC = 0.933), and the other two param-
eters had moderate diagnostic accuracy (AUC = 0.834, 
AUC = 0.832, respectively).
Other laboratory characteristics that are benefit to 
the differential diagnosis of LAHLH were reported. Li 
et al. (2014) had analyzed 69 adult HLH patients and 
found that the percentages of patients with Fbg < 1.5 g/L, 
PLT < 40 × 109/L and LDH > 1000 U/L in the LAHLH 
group were significantly higher than those in non-LAHLH 
patients. However, our result showed no significant dif-
ferences in Fbg, PLT, and LDH level between LAHLH 
and non-LAHLH group (data not shown). In addition, 
we found that the percentages of patients who had multi-
ple lymphadenopathy or multiple bone lesions in LAHLH 
group were significantly higher than those in non-LAHLH 
group (p = 0.004, p = 0.016, respectively). Solely enlarged 
lymph node with increased FDG uptake occurs in patients 
with reactive lymphoid hyperplasia or lymphoid tuber-
culosis. Two different situations of bone lesions were 
observed, including diffusely increased FDG uptake in 
systemic bones and increased FDG uptake in focal bone 
regions. Diffuse increased SUV uptake level in bones 
especially cancellous bones may reflect increased reactiv-
ity of hematopoiesis. According to a result of Inoue et al. 
(2009), BM F-18 FDG uptake depended on patient age 
and inflammatory activity, indicating BM activation. Some 
scholars maintained that the persistent secretion of high 
cytokine might lead to clinical signs and symptoms as 
well as increased F-18 FDG uptake in the BM and spleen 
(Inoue et al. 2009; Liu 2009). In our study, the incidence 
of multiple lymphadenopathy (accompanied by increased 
FDG uptake) and multiple bone lesions in LAHLH patients 
were significantly higher than those in non-LAHLH group. 
Therefore, we believe that multiple sites of lymphadenopa-
thy and bone lesions with increased FDG uptake may be 
prompted to multiple invasion and metastasis of lym-
phoma, thus indicating lymphoma-related HLH than sim-
ply increased SUVBM and SUVLN.
F18-FDG PET–CT can not only help to the differen-
tial diagnosis of sHLH, but also help to the assessment of 
therapeutic response (Cronin et al. 2010). Convincing evi-
dence showed that persistent FDG uptake after 2–4 cycles 
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of chemotherapy is associated with poor outcome in Hodg-
kin lymphoma and non-Hodgkin lymphoma (Hutchings 
et al. 2006; Mikhaeel et al. 2005). And Suga et al. (2010) 
reported, in a case of T cell lymphoma-associated HLH, 
sites of hypermetabolic abnormalities which existed at first 
visit and disappeared after taking 6 months of chemoimmu-
notherapy indicating remission of disease. There were five 
highly suspected LAHLH patients in our study received a 
second PET–CT scan after lymphoma-chemotherapy, of 
whom the PET–CT parameters had markedly decreased.
Since HLH can be rapidly fatal without specific inter-
vention, it is recommended that treatment be started when 
there is a high clinical suspicion, even when results of some 
diagnostic studies are still pending (Filipovich 2009). Park 
et al. (2012) analyzed the treatment outcome and prognos-
tic factors of sHLH and found that patients whose treatment 
began within 5.5 days of the first hospital visit were more 
likely to survive. Therefore, earlier therapeutic interven-
tion is the key to save lives. For unexplained sHLH patients 
who account for a relatively large proportion, to start ther-
apy after blindly pursuing pathological evidences may miss 
the best timing of treatment.
Various treatment strategies have been reported, such 
as HLH-94 protocol, HLH-2004 protocol, CHOP regimen, 
steroid pulse therapy, IVIG, TNF-α monoclonal antibody 
(Henzan et al. 2006), CD25 monoclonal antibody (Olin 
et al. 2008), and hematopoietic stem cell transplantation. 
However, due to the complexity of sHLH itself, treatment 
outcomes for adult cases have seldom been reported and 
varied widely. Since early application of etoposide with 
sufficient dose has a unique effect on EBV-associated 
HLH, etoposide-containing immunochemotherapy, like 
HLH-2004, has become a recommended treatment for 
childhood EBV-associated HLH (Imashuku et al. 1999, 
2001). After early use of HLH-2004 protocol, hypercy-
tokinemia was quickly under control, and clonal prolifera-
tive T/NK cell and activated macrophages were removed. 
With IVIG, infection-associated HLH patients seemed to 
benefit most with response rate of 78 %, but lymphoma-
associated patients seemed to be largely ineffective never-
theless (Larroche et al. 2000). It was proposed in a review 
that corticosteroids alone or combined with cyclosporin 
A and/or intravenous immunoglobulin might be appropri-
ate for low-risk situations, like RAHLH; early etoposide, 
antithymocyte globulin, and polychemotherapy were rec-
ommended for high-risk or refractory/relapse cases, such 
as Hodgkin’s disease or non-Hodgkin’s lymphoma (NHL) 
(Emmenegger et al. 2005). Although chemo-approach and 
etoposide were suggested, the five patients who accepted 
immunosuppressive therapy were unwilling to accept 
chemo-drugs due to lack of pathological evidences to 
lymphoma. Presented hyperbilirubinemia and dysfunc-
tion of liver in these patients, and high risk of infection, 
disease reactivation, and secondary malignancies associ-
ated with etoposide use (Ramos-Casals et al. 2014), made 
the patients object to etoposide. Till now, standardized and 
conformably approved regimens for adult HLH have not 
been well established.
Considering that CHOP regimen is a standard chemo-
therapy for aggressive NHL, it is considered as an effec-
tive regimen to treat HLH combined with malignant 
lymphoma (Shin et al. 2008). Although based on a small 
number of patients in the current study, lymphoma-chem-
otherapy shows a therapeutic potential in highly suspected 
LAHLH patients. In our study, compared with immuno-
suppressive therapy, highly suspected LAHLH patients 
who initially received lymphoma-chemotherapy have 
significantly higher CR rate and relatively favorable prog-
nosis. Although it is recommended that the first goal of 
therapy in adult HLH patients is to suppress the unregu-
lated hyper-inflammation, while the second is to identify 
and treat the underlying triggers (Kleynberg and Schil-
ler 2012). However, our results indicate that lymphoma-
chemotherapies that treat the underlying lymphoma 
should be the first intervention for highly suspected 
LAHLH. Immunosuppressive or cytokine-regulating ther-
apies could not reduce the soaring cytokines from the root 
causes.
In conclusion, we showed that PET–CT plays an impor-
tant role in confirming the diagnosis of LAHLH without 
pathologic evidence. Patient in LAHLH group had remark-
ably higher levels of SUVSp, SUVBM, SUVLD, SUVmax, 
SUVLD/Li, and SUVmax/Li than those in non-LAHLH group. 
In addition, sHLH patients who presented in PET–CT 
images with multiple lymphadenopathy and/or multiple 
bone lesions accompanied by increased FDG uptake were 
more likely to be LAHLH. For the initial treatment of these 
highly suspected LAHLH, lymphoma-chemotherapy, rather 
than immunosuppressive therapy (high-dose corticoster-
oid plus IVIG), may have a relatively favorable effect and 
better clinical outcomes. In conclusion, for sHLH patients 
without etiological evidence, PET–CT has high diagnostic 
value in detection of lymphoma. Once highly suspected as 
LAHLH by PET–CT, lymphoma-chemotherapy should be 
initially applied to improve their prognosis.
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